Regeneron Pharmaceuticals, Inc.
805.02USD
-14.0700 (-1.72%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on REGN.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $16.19▲ | $13.21 | 3 | 2 |
| Next quarter | $20.44▲ | $12.92 | 6 | 1 |
| Current year | $58.85▲ | $45.85 | 9 | 1 |
| Next year | $52.03▲ | $47.4 | 5 | 3 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $10.21 | $14.29 | +4.08 (+40.0%) |
| 2026-03-31 | $8.9 | $9.47 | +0.57 (+6.4%) |
| 2025-12-31 | $10.75 | $11.44 | +0.69 (+6.4%) |
| 2025-09-30 | $9.64 | $11.83 | +2.19 (+22.7%) |
556 ratings from 45 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| TD Cowen | Maintained | Buy | $960 $980 | Oct 21, 2026 |
| Piper Sandler | Maintained | Overweight | $854 $865 | Oct 19, 2026 |
| UBS | Upgraded from Neutral | Buy | $660 $978 | Oct 15, 2026 |
| RBC Capital | Maintained | Sector Perform | $737 $810 | Oct 8, 2026 |
| Truist Securities | Maintained | Buy | $772 $780 | Oct 7, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $758 $779 | Oct 7, 2026 |
| JP Morgan | Maintained | Overweight | $900 $950 | Oct 6, 2026 |
| Jefferies | Maintained | Buy | $870 $930 | Oct 1, 2026 |
| Argus Research | Upgraded from Hold | Buy | $850 | Oct 1, 2026 |
| RBC Capital | Reiterated | Sector Perform | $737 | Sep 29, 2026 |
| HSBC | Maintained | Buy | $800 $920 | Sep 10, 2026 |
| Leerink Partners | Maintained | Market Perform | $641 $824 | Aug 17, 2026 |
| Citigroup | Maintained | Neutral | $700 $740 | Aug 3, 2026 |
| Guggenheim | Maintained | Buy | $1,000 $1,030 | Aug 3, 2026 |
| RBC Capital | Maintained | Sector Perform | $696 $737 | Jul 31, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $730 $758 | Jul 31, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $750 $795 | Jul 31, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $700 $750 | Jul 31, 2026 |
| Truist Securities | Maintained | Buy | $769 $772 | Jul 31, 2026 |
| Guggenheim | Maintained | Buy | $995 $1,000 | Jul 21, 2026 |
| Piper Sandler | Maintained | Overweight | $855 $854 | Jul 9, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $788 $730 | Jul 8, 2026 |
| RBC Capital | Maintained | Sector Perform | $707 $696 | Jul 7, 2026 |
| Truist Securities | Maintained | Buy | $778 $769 | Jul 7, 2026 |
| Benchmark | Upgraded from Hold | Buy | $185 | Jul 7, 2026 |
111 filings from 21 insiders · 5 buy / 6 sell over 6m
Officers and directors of REGN, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| MURPHY ANDREW JOfficer, Co-Chief Scientific Officer | Sell | 6 | $753.76 | $5k | Oct 14, 2026 |
| MURPHY ANDREW JOfficer, Co-Chief Scientific Officer | Sell | 35 | $755.91 | $26k | Oct 14, 2026 |
| MURPHY ANDREW JOfficer, Co-Chief Scientific Officer | Sell | 16 | $757.68 | $12k | Oct 14, 2026 |
| MURPHY ANDREW JOfficer, Co-Chief Scientific Officer | Sell | 24 | $758.16 | $18k | Oct 14, 2026 |
| MURPHY ANDREW JOfficer, Co-Chief Scientific Officer | Sell | 14 | $759.96 | $11k | Oct 14, 2026 |
| MURPHY ANDREW JOfficer, Co-Chief Scientific Officer | Sell | 74 | $760.65 | $56k | Oct 14, 2026 |
| MURPHY ANDREW JOfficer, Co-Chief Scientific Officer | Sell | 27 | $761.36 | $21k | Oct 14, 2026 |
| MURPHY ANDREW JOfficer, Co-Chief Scientific Officer | Sell | 55 | $762.57 | $42k | Oct 14, 2026 |
| MURPHY ANDREW JOfficer, Co-Chief Scientific Officer | Sell | 25 | $763.76 | $19k | Oct 14, 2026 |
| MURPHY ANDREW JOfficer, Co-Chief Scientific Officer | Sell | 219 | $764.40 | $167k | Oct 14, 2026 |
| MURPHY ANDREW JOfficer, Co-Chief Scientific Officer | Sell | 271 | $765.39 | $207k | Oct 14, 2026 |
| MURPHY ANDREW JOfficer, Co-Chief Scientific Officer | Sell | 279 | $766.47 | $214k | Oct 14, 2026 |
| MURPHY ANDREW JOfficer, Co-Chief Scientific Officer | Sell | 192 | $767.39 | $147k | Oct 14, 2026 |
| MURPHY ANDREW JOfficer, Co-Chief Scientific Officer | Sell | 105 | $768.33 | $81k | Oct 14, 2026 |
| MURPHY ANDREW JOfficer, Co-Chief Scientific Officer | Sell | 127 | $769.30 | $98k | Oct 14, 2026 |
| MURPHY ANDREW JOfficer, Co-Chief Scientific Officer | Sell | 12 | $770.20 | $9k | Oct 14, 2026 |
| MURPHY ANDREW JOfficer, Co-Chief Scientific Officer | Sell | 283 | $771.56 | $218k | Oct 14, 2026 |
| MURPHY ANDREW JOfficer, Co-Chief Scientific Officer | Sell | 211 | $772.56 | $163k | Oct 14, 2026 |
| MURPHY ANDREW JOfficer, Co-Chief Scientific Officer | Sell | 224 | $773.40 | $173k | Oct 14, 2026 |
| MURPHY ANDREW JOfficer, Co-Chief Scientific Officer | Sell | 121 | $774.48 | $94k | Oct 14, 2026 |
No analyst notes on REGN yet.
Analyst Ratings
27 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 4 | 15 | 8 | 0 | 1 | Buy2.25 |
| 1 mo ago | 4 | 13 | 9 | 0 | 1 | Buy2.30 |
| 2 mo ago | 4 | 14 | 9 | 0 | 1 | Buy2.29 |
| 3 mo ago | 4 | 14 | 10 | 0 | 0 | Buy2.21 |
Members whose judged calls on REGN have played out most reliably.
No settled calls on REGN yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice